perifosine has been researched along with panobinostat in 2 studies
| Studies (perifosine) | Trials (perifosine) | Recent Studies (post-2010) (perifosine) | Studies (panobinostat) | Trials (panobinostat) | Recent Studies (post-2010) (panobinostat) |
|---|---|---|---|---|---|
| 245 | 31 | 140 | 678 | 95 | 593 |
| Protein | Taxonomy | perifosine (IC50) | panobinostat (IC50) |
|---|---|---|---|
| Histone deacetylase 8 | Schistosoma mansoni | 0.45 | |
| Histone deacetylase 3 | Homo sapiens (human) | 0.2031 | |
| Bromodomain-containing protein 4 | Homo sapiens (human) | 0.005 | |
| Cytochrome P450 3A5 | Homo sapiens (human) | 0.0033 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.3792 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.181 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.9434 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.2527 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.007 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.8396 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.46 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.2307 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.5825 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.3424 | |
| Histone deacetylase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.0025 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 0.002 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Orlowski, RZ | 1 |
| Iida, S; Ri, M | 1 |
2 review(s) available for perifosine and panobinostat
| Article | Year |
|---|---|
Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunologic Factors; Indoles; Multiple Myeloma; Oligopeptides; Panobinostat; Phosphorylcholine; Piperidines; Proteasome Inhibitors; Pyridines; Remission Induction; Thalidomide; Thiazoles; Treatment Outcome; Vorinostat | 2013 |
[Determinants of sensitivity to proteasome inhibitors and strategies to overcome acquired resistance to bortezomib in multiple myeloma].
Topics: Activating Transcription Factor 3; Activating Transcription Factor 4; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase 5; Cytokines; Dexamethasone; DNA-Binding Proteins; Drug Discovery; Drug Resistance, Neoplasm; Humans; Hydroxamic Acids; Indoles; Kruppel-Like Transcription Factors; Molecular Targeted Therapy; Multiple Myeloma; Nicotinamide Phosphoribosyltransferase; Oligopeptides; Panobinostat; Phosphorylcholine; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Regulatory Factor X Transcription Factors; Toyocamycin; Transcription Factors | 2014 |